P1.23-08 Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY(2023)
摘要
The incremental clinical value of performing both tissue and plasma next-generation sequencing (NGS) to detect actionable alterations (AA) in advanced non-small cell lung cancer (aNSCLC) has not been comprehensively assessed. We aimed to study the clinical utility of performing both techniques in patients with newly diagnosed aNSCLC.
更多查看译文
关键词
Next-generation sequencing,Advanced non-small cell lung cancer,Actionable alterations
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要